Alzheimer’s disease is a major global problem and now one of the leading causes of death in the United States. We have recently seen the publication of the first examples of the reversal of cognitive decline in early Alzheimer’s disease and its precursors, mild cognitive impairment (MCI) and subjective cognitive impairment (SCI). The successful protocol is a personalized, multi-modal approach that involves subtyping of Alzheimer’s and addressing dozens of factors that contribute to cognitive decline.